Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide for cutaneous lupus erythematosus
2009-016508-21Phase 4Completed
- Sponsor
- Vall d'Hebron University Hospital
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lenalidomide in cutaneous lupus erythematosus (CLE) and lupus erythematosus (SLE), sponsored by Vall d'Hebron University Hospital. Primary endpoints: Complete remission at week 12 by CLASI, Partial remission at week 12 by CLASI and 1 more. Started Dec 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
cutaneous lupus erythematosus (CLE)lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2009-016508-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016508-21.